News/ News/ R&D/ Sales and Marketing/ Top stories/ US AstraZeneca spins out biotech to focus on autoimmune candidates Andrew McConaghie AstraZeneca, Viela Bio 0 Comment AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. Share X AstraZeneca spins out biotech to focus on autoimmune candidates https://pharmaphorum.com/news/astrazeneca-spins-biotech-focus-autoimmune-candidates/